What question did this study set out to answer?

To assess the therapeutic role, efficacy, and safety profile of aspirin therapy across primary and secondary cardiovascular disease prevention.

September 20, 2026Journal of the American College of CardiologyOpen Access

The Role of Aspirin in Cardiovascular Prevention

Q: What is the clinical evidence from this study?

Study design: Review. Population: Cardiovascular disease and aspirin resistance. Intervention: Aspirin.

View Full Paper

Ask AI

Bookmark

Key result

Aspirin resistance leaves up to 60% of long-term patients at high risk for thrombotic events.

Design

Review article

Authors

AGArmen Yuri Gasparyan TWTimothy Watson GLGregory Y.H. Lip

Discussion

Member takes

Overview

Review reveals varied benefits of aspirin in cardiovascular prevention, highlighting the trade-off between ischemic event reduction and bleeding risk.

Key Points

To assess the therapeutic role, efficacy, and safety profile of aspirin therapy across primary and secondary cardiovascular disease prevention.
Synthesized findings from clinical trials and observational studies evaluating aspirin across distinct cardiovascular risk strata.
Assessed comparative rates of ischemic cardiovascular events against major hemorrhagic complications, particularly gastrointestinal and intracranial bleeding.
In secondary prevention, daily aspirin therapy consistently demonstrates substantial reductions in recurrent myocardial infarction, stroke, and cardiovascular mortality.
In primary prevention, modest absolute reductions in vascular events are frequently offset by significant increases in major bleeding events.

PICO

Population

Cardiovascular disease and aspirin resistance

Exposure / Comparator

Aspirin

Limitations

Only a limited number of clinical studies have convincingly investigated the importance of aspirin resistance.
Few studies are of a sufficient scale, well designed, and prospective with standard aspirin doses.
Most studies do not sufficiently address noncompliance as a cause of apparent aspirin resistance.

Cite This Study

Gasparyan et al. (2008) conducted a review in Cardiovascular disease and aspirin resistance. Aspirin was evaluated. Aspirin resistance is estimated to affect 5.5% to 60% of patients receiving long-term therapy, leaving them at substantial risk for thrombotic events despite treatment.

synapsesocial.com/papers/6ab04d16cdc128587b47ec95 https://doi.org/10.1016/j.jacc.2007.11.080

View Full Paper

Ask AI

Bookmark

September 20, 2026Journal of the American College of CardiologyOpen Access

The Role of Aspirin in Cardiovascular Prevention

View Full Paper

Ask AI

Bookmark

Key result

Aspirin resistance leaves up to 60% of long-term patients at high risk for thrombotic events.

Design

Review article

Authors

AGArmen Yuri Gasparyan TWTimothy Watson GLGregory Y.H. Lip

Discussion

Member takes

Overview

Review reveals varied benefits of aspirin in cardiovascular prevention, highlighting the trade-off between ischemic event reduction and bleeding risk.

Key Points

To assess the therapeutic role, efficacy, and safety profile of aspirin therapy across primary and secondary cardiovascular disease prevention.
Synthesized findings from clinical trials and observational studies evaluating aspirin across distinct cardiovascular risk strata.
Assessed comparative rates of ischemic cardiovascular events against major hemorrhagic complications, particularly gastrointestinal and intracranial bleeding.
In secondary prevention, daily aspirin therapy consistently demonstrates substantial reductions in recurrent myocardial infarction, stroke, and cardiovascular mortality.
In primary prevention, modest absolute reductions in vascular events are frequently offset by significant increases in major bleeding events.

PICO

Population

Cardiovascular disease and aspirin resistance

Exposure / Comparator

Aspirin

Limitations

Only a limited number of clinical studies have convincingly investigated the importance of aspirin resistance.
Few studies are of a sufficient scale, well designed, and prospective with standard aspirin doses.
Most studies do not sufficiently address noncompliance as a cause of apparent aspirin resistance.

Cite This Study

synapsesocial.com/papers/6ab04d16cdc128587b47ec95 https://doi.org/10.1016/j.jacc.2007.11.080

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark